Stay updated on Pembrolizumab and TKI in CML MRD Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.
Latest updates to the Pembrolizumab and TKI in CML MRD Clinical Trial page
- Check5 days agoChange DetectedNo additions or deletions are visible in the provided data; the page appears unchanged.SummaryDifference0.0%
- Check12 days agoChange DetectedScreenshot comparison shows no content additions or deletions to core study information. The visible sections appear unchanged, including the brief summary, objectives, and eligibility criteria.SummaryDifference0.0%
- Check19 days agoChange DetectedRevision: v3.5.0 has been added to the page. The previous revision label v3.4.3 has been removed.SummaryDifference0.0%
- Check26 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%
- Check33 days agoChange DetectedAdded updated study-record timestamps (e.g., last update posted and last update submitted) and removed older timestamps; no changes to trial details or criteria.SummaryDifference0.1%
- Check55 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding operating status notice and Revision: v3.4.1.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab and TKI in CML MRD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.